Silibinin
- Generic Name
- Silibinin
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22O10
- CAS Number
- 22888-70-6
- Unique Ingredient Identifier
- 33X338MNE4
- Background
Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin is presented as a mixture of two diastereomers, silybin A and silybin B, which are found in an approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.
- Indication
Currently being tested as a treatment of severe intoxications with hepatotoxic substances, such as death cap (Amanita phalloides) poisoning.
- Associated Conditions
- Acute Hepatitis, Amanita Poisoning, Cirrhosis of the Liver, Clinical Deterioration of the Liver, Fatty Liver Disease, Hepatitis, Chronic, Non Alcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Recurrent Hepatitis, Severe alcoholic liver disease, Uncomplicated hepatic dysfunction
Trial of Indole-3-Carbinol and Silibinin
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 21
- Registration Number
- NCT03687073
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
THISTLE - The HIV-HCV Silibinin Trial
- Conditions
- Hepatitis CHIV
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 20
- Registration Number
- NCT01816490
- Locations
- 🇨🇭
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
- Conditions
- HCV Recurrence After Liver Transplantation
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 14
- Registration Number
- NCT01535092
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
- Conditions
- Hepatitis C Virus Recurrence
- Interventions
- Drug: Saline
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 20
- Registration Number
- NCT01518933
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
- Conditions
- Amanita PoisoningMushroom PoisoningAmatoxin PoisoningLiver Failure
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Mylan Specialty, LP
- Target Recruit Count
- 148
- Registration Number
- NCT00915681
- Locations
- 🇺🇸
Recruitment Hot Line for the United States, Somerset, New Jersey, United States
🇺🇸Mylan Specialty LLP, Morgantown, West Virginia, United States
Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 70
- Registration Number
- NCT00684268
- Locations
- 🇦🇹
Medical University of Vienna, Wien, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.